Skip to main content

Advertisement

ADVERTISEMENT

EGFR Videos

Nicolas Girard, MD, Institut Curie
Videos
10/23/2023

Featuring Nicolas Girard, MD

Featuring Nicolas Girard, MD
Prof Nicolas Girard, MD, discusses primary results from the phase 3 PAPILLON study comparing amivantamab plus chemotherapy vs chemotherapy alone for the first-line treatment of patients with EGFR exon 20 insertion-mutated advanced NSCLC.
Prof Nicolas Girard, MD, discusses primary results from the phase 3 PAPILLON study comparing amivantamab plus chemotherapy vs chemotherapy alone for the first-line treatment of patients with EGFR exon 20 insertion-mutated advanced NSCLC.
Prof Nicolas Girard, MD,...
10/23/2023
Oncology
Joshua Sabari, MD, NYU Langone Health, New York, NY
Videos
05/30/2023
Joshua Sabari, MD, NYU Langone Health discusses mortality among patients with EGFR-mutated advanced non-small cell lung cancer after starting first-line treatment with osimertinib.
Joshua Sabari, MD, NYU Langone Health discusses mortality among patients with EGFR-mutated advanced non-small cell lung cancer after starting first-line treatment with osimertinib.
Joshua Sabari, MD, NYU Langone...
05/30/2023
Oncology
Heather Wakelee, MD, Stanford University, Palo Alto, California
Videos
05/18/2023
Heather Wakelee, MD, discusses first-line treatment options for patients with EGFR-mutant non-small cell lung cancer.
Heather Wakelee, MD, discusses first-line treatment options for patients with EGFR-mutant non-small cell lung cancer.
Heather Wakelee, MD, discusses...
05/18/2023
Oncology

Advertisement

Helena Yu, MD, Memorial Sloan Kettering Cancer Center, New York, NY
Videos
05/17/2023
At the 2023 Great Debates and Updates Conference in Chicago, IL, Helena Yu, MD, discusses the challenges of primary and secondary resistance to EGFR tyrosine kinase inhibitors among patients with lung cancer.
At the 2023 Great Debates and Updates Conference in Chicago, IL, Helena Yu, MD, discusses the challenges of primary and secondary resistance to EGFR tyrosine kinase inhibitors among patients with lung cancer.
At the 2023 Great Debates and...
05/17/2023
Oncology
Helena Yu, MD
Videos
11/15/2022
Helena Yu, MD, discusses the treatment of patients with early-stage EGFR-mutated lung cancer with a focus on improving overall survival, a topic she presented at the 2022 Great Debates and Updates in Lung Cancer meeting in New York.
Helena Yu, MD, discusses the treatment of patients with early-stage EGFR-mutated lung cancer with a focus on improving overall survival, a topic she presented at the 2022 Great Debates and Updates in Lung Cancer meeting in New York.
Helena Yu, MD, discusses the...
11/15/2022
Oncology
Helena Yu, MD
Videos
11/07/2022
Helena Yu, MD, shares exciting new developments and potential treatments in the first- and second-line settings for patients with EGFR-mutated lung cancer, a topic she presented at the 2022 Great Debates and Updates in Lung Cancer.
Helena Yu, MD, shares exciting new developments and potential treatments in the first- and second-line settings for patients with EGFR-mutated lung cancer, a topic she presented at the 2022 Great Debates and Updates in Lung Cancer.
Helena Yu, MD, shares exciting...
11/07/2022
Oncology

Advertisement

Shirish Gadgeel
Videos
09/29/2021
Shirish Gadgeel, MD, Henry Ford Health System, Detriot, MI, shares insight on pembrolizumab in combination with platinum-based chemotherapy in recurrent EGFR/ALK-Positive non-small cell lung cancer.
Shirish Gadgeel, MD, Henry Ford Health System, Detriot, MI, shares insight on pembrolizumab in combination with platinum-based chemotherapy in recurrent EGFR/ALK-Positive non-small cell lung cancer.
Shirish Gadgeel, MD, Henry Ford...
09/29/2021
Oncology
Dr Spira
Videos
09/10/2021
Alexander Spira, MD, PhD, FACP, discusses new evidence supporting the use of the amivantamab in the treatment of patients with NSCLC with MET exon 14 skipping (METex14) mutations, to be presented at the IASLC 2021 World Conference on Lung...
Alexander Spira, MD, PhD, FACP, discusses new evidence supporting the use of the amivantamab in the treatment of patients with NSCLC with MET exon 14 skipping (METex14) mutations, to be presented at the IASLC 2021 World Conference on Lung...
Alexander Spira, MD, PhD, FACP,...
09/10/2021
Oncology
Dr Santos, Dr Raez, Dr Albrecht, Dr Socinski, Dr Heymach
Debates and Roundtables
07/14/2021
In this virtual roundtable discussion, experts sat down with Oncology Learning Network to discuss EGFR sensitive mutations in patients with lung cancer.
In this virtual roundtable discussion, experts sat down with Oncology Learning Network to discuss EGFR sensitive mutations in patients with lung cancer.
In this virtual roundtable...
07/14/2021
Oncology

Advertisement

Dr Le Shares Promising Data on Poziotinib for NSCLC With EGFR or HER2 Mutations
Videos
04/28/2021
Xiuning Le, MD, PhD, discusses results from the ZENITH20 trial, which showed that twice daily poziotinib improved AEs and retained anti-tumour activity in EGFR+ or HER2+ NSCLC.
Xiuning Le, MD, PhD, discusses results from the ZENITH20 trial, which showed that twice daily poziotinib improved AEs and retained anti-tumour activity in EGFR+ or HER2+ NSCLC.
Xiuning Le, MD, PhD, discusses...
04/28/2021
Oncology

Advertisement